SOMALOGIC, INC

BOULDER, CO · CIK 0001126461 · Medtech · Acquired

Proteomics platform for protein detection and measurement across the human proteome

somalogic.com →
Grants
$302K
3 awards
Sector median: 1
Raised
$357M
9 Form D · Dec 2020
70 months since last filing
Contracts
—
No federal contracts on record
Patents
40
25 granted · 15 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Aptamer Development for Cancer Diagnosis and Management$99,853
Federal grantDepartment of Health and Human Services · Phase I · Development and Application of Aptamer Arrays$100,166
Federal grantDepartment of Health and Human Services · Phase I · Proteomics-based Diagnosis and Management of RA$101,600
Private capital raisedForm D · SEC$4,999,995
Private capital raisedForm D · SEC$14,999,998
Private capital raisedForm D · SEC$9,999,997
Private capital raisedForm D · SEC$16,490,873
Private capital raisedForm D · SEC$162,972,388
Private capital raisedForm D · SEC$44,879,987
Private capital raisedForm D · SEC$147,180
Private capital raisedForm D · SEC$969
Private capital raisedForm D · SEC$102,974,957
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1207LIFE SEAL VASCULAR, INC.——
1208NVE CORPORATION——
1209Merit Financial Solutions, Inc.—$550K
1210SOMALOGIC, INC—$357M
1211Boon Logic, Inc.—$3.9M
1212Huxley Medical, Inc.—$34M
1213MESA PHOTONICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 34 related persons
  • Eli CasdinDirector
  • Larry GoldDirector · Executive Officer · Promoter
  • LARRY GOLDDirector · Executive Officer
  • Melody HarrisExecutive Officer
  • Byron HewettDirector · Executive Officer
  • NEBOSA JANJICExecutive Officer
  • Scott KothlowExecutive Officer
  • SCOTT KOTHLOWExecutive Officer
  • Charles LillisDirector
  • CHARLES LILLISDirector
  • Teresa LipsceyExecutive Officer
  • Anne MarguliesDirector
  • Jessica MathewsDirector
  • JESSICA MATHEWSDirector
  • Mark MessenbaughExecutive Officer
  • Franck MoisanDirector
  • Steve MorrissettExecutive Officer
  • Steven MorrissettExecutive Officer
  • Daniel MuehlExecutive Officer
  • KUNIAKI NATSUMEDirector
  • Matt NorkunasExecutive Officer
  • Matthew NorkunasExecutive Officer
  • HAROLD NUSSENFELDDirector
  • Richard PostDirector
  • Terry RandallDirector
  • Al ReynoldsDirector
  • Alister ReynoldsDirector · Executive Officer
  • ALISTER REYNOLDSDirector
  • NICHOLAS SACCAMANOExecutive Officer
  • Takayuki ShiratsuchiDirector
  • Roy SmytheDirector · Executive Officer
  • Jun WangDirector
  • STEPHEN WILLIAMSExecutive Officer
  • Youichi YabuuchiDirector

Patents

USPTO · 25 granted of 40
  • Controlling Intersample Analyte Variability in Complex Biological Matricesapplication
  • Next-generation Sequencing For Protein Measurementapplication
  • Monoclonal Polony Generation Using Nucleic Acid Supramolecular Structuresapplication
  • Click-Labeled Nucleosides and Phosphoramiditesapplication
  • Assay Array Plateapplication
  • Methods Of Detecting A Leak From A Subarray Of A Microarray Chipapplication
  • Multiplexed Analyses of Test Samplesapplication
  • Oligonucleotides Comprising Modified Nucleosidesapplication
  • Methods of Solid-Phase Nucleic Acid Hybridizationapplication
  • Proteomic Assay Using Quantum Sensorsgranted
  • Lung Cancer Biomarkers and Uses Thereofgranted
  • Post-selex Modification Methodsgranted

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.